Loading insider details...
Beta
Latest Form 4 (Sep 3, 2026): Exercise/Conversion of 20,000 AUTL shares, $47.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Autolus Therapeutics plc (AUTL) | Exercise/Conversion | 20,000 | $47.0K |
| Feb 20, 2025 | Adaptimmune Therapeutics PLC (ADAP) | Grant/Award | 1,612,032 | n/a |
| Jan 15, 2025 | Adaptimmune Therapeutics PLC (ADAP) | Sale | 12,991 | $7.5K |
| Jun 18, 2024 | Adaptimmune Therapeutics PLC (ADAP) | Sale | 24,531 | $22.8K |
| Mar 18, 2024 | Adaptimmune Therapeutics PLC (ADAP) | Grant/Award | 5,088,864 | n/a |
| Jul 5, 2023 | Allovir, Inc. (ALVR) | Grant/Award | 147,000 | n/a |
| Feb 1, 2023 | Adaptimmune Therapeutics PLC (ADAP) | Sale | 11,890 | $22.2K |
| Jan 18, 2023 | Adaptimmune Therapeutics PLC | Grant/Award | 1,407,072 | n/a |
| Aug 2, 2022 | Adaptimmune Therapeutics PLC (ADAP) | Sale | 21,040 | $37.3K |
| Feb 1, 2022 | Adaptimmune Therapeutics PLC (ADAP) | Grant/Award | 3,376,992 | n/a |